Logo image of CLLS

CELLECTIS - ADR (CLLS) Stock Fundamental Analysis

NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD

1.56  +0.04 (+2.63%)

Fundamental Rating

3

Overall CLLS gets a fundamental rating of 3 out of 10. We evaluated CLLS against 561 industry peers in the Biotechnology industry. CLLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, CLLS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CLLS has reported negative net income.
CLLS had a positive operating cash flow in the past year.
CLLS had negative earnings in each of the past 5 years.
In the past 5 years CLLS reported 4 times negative operating cash flow.
CLLS Yearly Net Income VS EBIT VS OCF VS FCFCLLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

CLLS has a Return On Assets of -14.12%. This is amongst the best in the industry. CLLS outperforms 81.82% of its industry peers.
With a decent Return On Equity value of -41.34%, CLLS is doing good in the industry, outperforming 69.52% of the companies in the same industry.
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
CLLS Yearly ROA, ROE, ROICCLLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CLLS's Gross Margin of 4.64% is fine compared to the rest of the industry. CLLS outperforms 72.01% of its industry peers.
CLLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLLS Yearly Profit, Operating, Gross MarginsCLLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLLS has been increased compared to 1 year ago.
Compared to 5 years ago, CLLS has more shares outstanding
Compared to 1 year ago, CLLS has an improved debt to assets ratio.
CLLS Yearly Shares OutstandingCLLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLLS Yearly Total Debt VS Total AssetsCLLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -1.06, we must say that CLLS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.06, CLLS is in the better half of the industry, outperforming 60.25% of the companies in the same industry.
The Debt to FCF ratio of CLLS is 4.88, which is a neutral value as it means it would take CLLS, 4.88 years of fcf income to pay off all of its debts.
CLLS's Debt to FCF ratio of 4.88 is amongst the best of the industry. CLLS outperforms 93.40% of its industry peers.
CLLS has a Debt/Equity ratio of 0.65. This is a neutral value indicating CLLS is somewhat dependend on debt financing.
CLLS has a worse Debt to Equity ratio (0.65) than 75.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Altman-Z -1.06
ROIC/WACCN/A
WACC6.23%
CLLS Yearly LT Debt VS Equity VS FCFCLLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

CLLS has a Current Ratio of 1.73. This is a normal value and indicates that CLLS is financially healthy and should not expect problems in meeting its short term obligations.
CLLS has a worse Current ratio (1.73) than 79.86% of its industry peers.
A Quick Ratio of 1.73 indicates that CLLS should not have too much problems paying its short term obligations.
CLLS has a Quick ratio of 1.73. This is in the lower half of the industry: CLLS underperforms 78.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
CLLS Yearly Current Assets VS Current LiabilitesCLLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.54%, which is quite impressive.
The Revenue has grown by 435.37% in the past year. This is a very strong growth!
CLLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.44% yearly.
EPS 1Y (TTM)45.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
Revenue 1Y (TTM)435.37%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%85.13%

3.2 Future

CLLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -75.28% yearly.
CLLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.02% yearly.
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue Next Year63.01%
Revenue Next 2Y30.93%
Revenue Next 3Y12.51%
Revenue Next 5Y30.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLLS Yearly Revenue VS EstimatesCLLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
CLLS Yearly EPS VS EstimatesCLLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLLS. In the last year negative earnings were reported.
Also next year CLLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLLS Price Earnings VS Forward Price EarningsCLLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

CLLS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CLLS is cheaper than 98.93% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.17
EV/EBITDA N/A
CLLS Per share dataCLLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

CLLS's earnings are expected to decrease with -75.28% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%

More info and screens

0

5. Dividend

5.1 Amount

CLLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS - ADR

NASDAQ:CLLS (5/22/2025, 2:05:08 PM)

1.56

+0.04 (+2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04
Inst Owners20.91%
Inst Owner Change-27.51%
Ins Owners3.88%
Ins Owner ChangeN/A
Market Cap156.45M
Analysts85.71
Price Target7.27 (366.03%)
Short Float %0.61%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82%
Min EPS beat(2)18.3%
Max EPS beat(2)145.69%
EPS beat(4)4
Avg EPS beat(4)73.41%
Min EPS beat(4)6.42%
Max EPS beat(4)145.69%
EPS beat(8)6
Avg EPS beat(8)27.22%
EPS beat(12)9
Avg EPS beat(12)23.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)108.7%
Min Revenue beat(2)55.84%
Max Revenue beat(2)161.56%
Revenue beat(4)4
Avg Revenue beat(4)91.56%
Min Revenue beat(4)50.31%
Max Revenue beat(4)161.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)29.61%
PT rev (3m)29.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)19.78%
Revenue NY rev (1m)46.67%
Revenue NY rev (3m)46.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.12
P/FCF 8.17
P/OCF 6.81
P/B 1.19
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)0.19
FCFY12.24%
OCF(TTM)0.23
OCFY14.69%
SpS0.74
BVpS1.31
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.64%
FCFM 25.96%
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Debt/EBITDA N/A
Cap/Depr 19.36%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -1.06
F-Score7
WACC6.23%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue 1Y (TTM)435.37%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%85.13%
Revenue Next Year63.01%
Revenue Next 2Y30.93%
Revenue Next 3Y12.51%
Revenue Next 5Y30.02%
EBIT growth 1Y35.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.35%
EBIT Next 3YN/A
EBIT Next 5Y-29.24%
FCF growth 1Y174.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y192.9%
OCF growth 3YN/A
OCF growth 5YN/A